Literature DB >> 19473634

The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure.

A Fahrleitner-Pammer1, H Dobnig, H P Dimai, H Holzer, T Benesch, K Borchhardt, D Cejka, M Haas.   

Abstract

AIMS: The influence of pre-dialysis chronic kidney disease (CKD) on bone is ill defined. Isolation of specific pathogenic mechanisms would improve the understanding and therapeutic options. We therefore investigated whether parathyroid dysfunction, altered vitamin D and hormonal status, or RANKL and OPG have an influence on bone mineral density (BMD) in patients with pre-dialysis renal failure. MATERIAL: 132 patients with chronic renal failure stage 1 - 5 (not yet on dialysis) were investigated in a cross sectional study. Osteoprotegerin (OPG), receptor activator of nuclear factor kB ligand (RANKL), parathyroid hormone (whole, intact and 7-84 fragment), bone markers, sex hormones, and vitamin D status were assessed together with femoral neck and trochanter z-score. Correlation and multivariate analyses were performed between the different parameters and BMD.
RESULTS: In the multivariate analysis a significant association was found between the femoral neck z-score and sRANKL (B = -0.45; p < 0.001), and OPG (B = 0.20; p < 0.05). A significant negative association was also found between the trochanter z-score and sRANKL (B = -0.32; p < 0.001). No associations were found between the trochanter z-score and OPG or the sRANKL/OPG ratio. The body mass index was the only additional marker associated with both FN z-score (B = 0.20, p < 0.05) and TR z-score (B = 0.20, p < 0.05). Neither markers of osteoblast nor osteoclast activity, or intact PTH, whole PTH, the PTH 7-84 fragment or vitamin D status were related to bone mineral density.
CONCLUSION: Our results demonstrate that the RANKL/RANK/OPG system is associated with bone mineral density in pre-dialysis chronic renal failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473634     DOI: 10.5414/cnp71652

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

Review 1.  Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?

Authors:  Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2010-08-16

2.  Determination of NF-κB and RANKL levels in peripheral blood osteoclast precursor cells in chronic kidney disease patients.

Authors:  Gülcan Güneş; Nil Doğruer Ünal; Gülçin Eskandari; Ahmet Kiykim; Özlem Bölgen Çimen; Gülhan Temel; Mehmet Burak Y Çimen
Journal:  Int Urol Nephrol       Date:  2018-04-11       Impact factor: 2.370

3.  RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-α.

Authors:  Kate Ann Deuell; Andrea Callegari; Cecilia M Giachelli; Michael E Rosenfeld; Marta Scatena
Journal:  J Vasc Res       Date:  2012-08-30       Impact factor: 1.934

4.  Increased calcification in osteoprotegerin-deficient smooth muscle cells: Dependence on receptor activator of NF-κB ligand and interleukin 6.

Authors:  Andrea Callegari; Matthew L Coons; Jerry L Ricks; Michael E Rosenfeld; Marta Scatena
Journal:  J Vasc Res       Date:  2014-03-07       Impact factor: 1.934

Review 5.  Bone mineral density in patients on maintenance dialysis.

Authors:  Csaba Ambrus; Adrienn Marton; Zsofia Klara Nemeth; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-12-29       Impact factor: 2.370

6.  Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study.

Authors:  Chang Seong Kim; Eun Hui Bae; Seong Kwon Ma; Seung Hyeok Han; Kyu Hun Choi; Joongyub Lee; Dong Wan Chae; Kook-Hwan Oh; Curie Ahn; Soo Wan Kim
Journal:  PLoS One       Date:  2016-11-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.